What are the clinical benefits of angiotensin receptor/neprilysin inhibitors compared with angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in the setting of heart failure ...
The use of sacubitril/valsartan (Entresto; Novartis) in patients with heart failure with reduced ejection fraction (HFrEF) appears to reduce the severity of mitral regurgitation (MR), potentially ...
Sacubitril/valsartan significantly reduces NT-proBNP levels in patients with heart failure with reduced ejection fraction (HFrEF) over 3 years, with no significant changes in sST2 and galectin-3.
Toronto, ON - A new meta-analysis comparing angiotensin receptor blockers (ARBs) to placebo or ACE inhibitors in heart failure patients "cannot claim that ARBs are superior" to ACE inhibitors in ...
"Medical Journeys" is a set of clinical resources reviewed by physicians, meant for the medical team as well as the patients they serve. Each episode of this journey through a disease state contains ...
The panel explores clinical evaluations, such as the PROVE-HF study and PARADIGM-HF trial. Ryan Haumschild, PharmD, MS, MBA: Discuss the results of the PARADIGM-HF trial (NCT01035255) and how it has ...
Although there are gaps in adherence to optimal medical therapy as recommended by heart failure guidelines, failure to prescribe up to the recommended treatment doses may not be a lapse on the part of ...
Close-up of senior black woman sorting weekly medication. Member of a black middle class America family. Currently, ACE inhibitors and ARBs are both recommended as first-line therapies for the ...
Credit: Getty Images. Currently, ACE inhibitors and ARBs are both recommended as first-line therapies for the treatment of hypertension according to US and European guidelines. Angiotensin receptor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results